RxDoctor Payments Data

Panchami Thomas, APRN

Psychiatric/Mental Health · Valrico, FLNPI 1336689819

Payments from drug & device makers

$148in general payments, 2019–2025

Across 7 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$46
  • Takeda Pharmaceuticals U.S.A., Inc.$24
  • Otsuka America Pharmaceutical, Inc.$21
  • Johnson & Johnson$21
  • Teva Pharmaceuticals USA, Inc.$19
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16

What the payments were for

  • Food & beverage$148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$148 in reported general payments places this provider in the 20th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$131,871
Medicare patients
278
Services billed
1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate164$547,651
Austedo XrDeutetrabenazine54$431,524
IngrezzaValbenazine Tosylate11$81,108
AustedoDeutetrabenazine17$80,793
RexultiBrexpiprazole42$62,181
VraylarCariprazine Hcl30$43,239
Risperidone ErRisperidone Microspheres20$42,087
Risperdal ConstaRisperidone Microspheres11$26,453
Memantine Hcl489$20,223
Aripiprazole269$18,360
LybalviOlanzapine/Samidorphan Malate11$16,657
Divalproex Sodium576$13,146
Olanzapine OdtOlanzapine157$13,021
Clozapine127$12,567
Fluphenazine Hcl56$11,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$21$574,104175 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$19$512,31771 claims
Otsuka America Pharmaceutical, Inc.Rexulti$21$62,18142 claims
AbbVieVraylar$46$43,23930 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$24$5,33212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Valrico

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →